Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2
Descripción del Articulo
Immunity against COVID-19 is crucial. Little is known about the mechanisms involved in stimulating antibody production against SARS-CoV-2 by the tumor necrosis factor alpha (TNF-α) and the exhaustion of T-cells. Objective: To evaluate the IgG (anti-spike) response, TNF-α, T-cell subsets, and their e...
| Autores: | , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2024 |
| Institución: | Universidad Peruana Cayetano Heredia |
| Repositorio: | Revistas - Universidad Peruana Cayetano Heredia |
| Lenguaje: | español |
| OAI Identifier: | oai:revistas.upch.edu.pe:article/5258 |
| Enlace del recurso: | https://revistas.upch.edu.pe/index.php/RMH/article/view/5258 |
| Nivel de acceso: | acceso abierto |
| Materia: | Anticuerpos citocinas COVID-19 inmunoglobulina G SARS-CoV-2 linfocitos T Antibodies cytokines immunoglobulin G T-Lymphocytes |
| id |
REVUPCH_4af0aaddd7df0b37ab72cb3bc36b75ab |
|---|---|
| oai_identifier_str |
oai:revistas.upch.edu.pe:article/5258 |
| network_acronym_str |
REVUPCH |
| network_name_str |
Revistas - Universidad Peruana Cayetano Heredia |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 Nivel de anticuerpos IgG, factor de necrosis tumoral y agotamiento de linfocitos T en personas vacunadas contra el SARS-CoV-2 |
| title |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 |
| spellingShingle |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 Lozada Requena, Ivan Anticuerpos citocinas COVID-19 inmunoglobulina G SARS-CoV-2 linfocitos T Antibodies cytokines COVID-19 immunoglobulin G SARS-CoV-2 T-Lymphocytes |
| title_short |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 |
| title_full |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 |
| title_fullStr |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 |
| title_full_unstemmed |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 |
| title_sort |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2 |
| dc.creator.none.fl_str_mv |
Lozada Requena, Ivan Paredes Inofuente, Diego |
| author |
Lozada Requena, Ivan |
| author_facet |
Lozada Requena, Ivan Paredes Inofuente, Diego |
| author_role |
author |
| author2 |
Paredes Inofuente, Diego |
| author2_role |
author |
| dc.subject.none.fl_str_mv |
Anticuerpos citocinas COVID-19 inmunoglobulina G SARS-CoV-2 linfocitos T Antibodies cytokines COVID-19 immunoglobulin G SARS-CoV-2 T-Lymphocytes |
| topic |
Anticuerpos citocinas COVID-19 inmunoglobulina G SARS-CoV-2 linfocitos T Antibodies cytokines COVID-19 immunoglobulin G SARS-CoV-2 T-Lymphocytes |
| description |
Immunity against COVID-19 is crucial. Little is known about the mechanisms involved in stimulating antibody production against SARS-CoV-2 by the tumor necrosis factor alpha (TNF-α) and the exhaustion of T-cells. Objective: To evaluate the IgG (anti-spike) response, TNF-α, T-cell subsets, and their exhaustion. Methods: Serum samples and peripheral mononuclear cells of subjects with infection (G1, n=07), asymptomatic (G2, n=08 y G3, n=10) vaccinated with three doses of the BNT162b2 (G1 and G2) or the ChAdOx1-S (G3) vaccines. ELISA determined the level of IgG and TNF-α, and flow cytometry determined the T-cell subsets and exhaustion. Results: No change was observed in the levels of IgG before and after vaccination. G1 significantly increased TNF-α levels after receiving the third vaccine dose. Total lymphocytes significantly decreased in G2, but CD3+ did not change. G3 had a reduction in LTCD4+ and an increase in PD-1+, LTCD8+, and PD-1+ before and after the third vaccine dose. A positive correlation was observed after the third vaccine dose in G3 among IgG and CD4+PD-1+(p=0.034) and CD8+PD-1+(p=0.028), respectively. Conclusions: Humoral (IgG) and inflammatory (TNF-α) responses were not modified significantly; the heterologous vaccine (G3) increased levels of CD4+ cells, a subset that sustains antiviral adaptative immunity, and avoids T-cell exhaustion. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-09-27 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed article Artículo evaluado por pares |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://revistas.upch.edu.pe/index.php/RMH/article/view/5258 10.20453/rmh.v35i3.5258 |
| url |
https://revistas.upch.edu.pe/index.php/RMH/article/view/5258 |
| identifier_str_mv |
10.20453/rmh.v35i3.5258 |
| dc.language.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.none.fl_str_mv |
https://revistas.upch.edu.pe/index.php/RMH/article/view/5258/5806 |
| dc.rights.none.fl_str_mv |
Derechos de autor 2024 Ivan Lozada Requena, Diego Paredes Inofuente http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Derechos de autor 2024 Ivan Lozada Requena, Diego Paredes Inofuente http://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidad Peruana Cayetano Heredia |
| publisher.none.fl_str_mv |
Universidad Peruana Cayetano Heredia |
| dc.source.none.fl_str_mv |
Revista Médica Herediana; Vol. 35 No. 3 (2024): Julio - Setiembre; 130-141 Revista Médica Herediana; Vol. 35 Núm. 3 (2024): Julio - Setiembre; 130-141 Revista Medica Herediana; v. 35 n. 3 (2024): Julio - Setiembre; 130-141 1729-214X 1018-130X reponame:Revistas - Universidad Peruana Cayetano Heredia instname:Universidad Peruana Cayetano Heredia instacron:UPCH |
| instname_str |
Universidad Peruana Cayetano Heredia |
| instacron_str |
UPCH |
| institution |
UPCH |
| reponame_str |
Revistas - Universidad Peruana Cayetano Heredia |
| collection |
Revistas - Universidad Peruana Cayetano Heredia |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1846787122028085248 |
| spelling |
Level of IgG antibodies, tumor necrosis factor alpha and T-cell exhaustion in persons vaccinated against SARS-CoV-2Nivel de anticuerpos IgG, factor de necrosis tumoral y agotamiento de linfocitos T en personas vacunadas contra el SARS-CoV-2Lozada Requena, IvanParedes Inofuente, DiegoAnticuerposcitocinasCOVID-19 inmunoglobulina GSARS-CoV-2linfocitos TAntibodiescytokinesCOVID-19immunoglobulin GSARS-CoV-2T-LymphocytesImmunity against COVID-19 is crucial. Little is known about the mechanisms involved in stimulating antibody production against SARS-CoV-2 by the tumor necrosis factor alpha (TNF-α) and the exhaustion of T-cells. Objective: To evaluate the IgG (anti-spike) response, TNF-α, T-cell subsets, and their exhaustion. Methods: Serum samples and peripheral mononuclear cells of subjects with infection (G1, n=07), asymptomatic (G2, n=08 y G3, n=10) vaccinated with three doses of the BNT162b2 (G1 and G2) or the ChAdOx1-S (G3) vaccines. ELISA determined the level of IgG and TNF-α, and flow cytometry determined the T-cell subsets and exhaustion. Results: No change was observed in the levels of IgG before and after vaccination. G1 significantly increased TNF-α levels after receiving the third vaccine dose. Total lymphocytes significantly decreased in G2, but CD3+ did not change. G3 had a reduction in LTCD4+ and an increase in PD-1+, LTCD8+, and PD-1+ before and after the third vaccine dose. A positive correlation was observed after the third vaccine dose in G3 among IgG and CD4+PD-1+(p=0.034) and CD8+PD-1+(p=0.028), respectively. Conclusions: Humoral (IgG) and inflammatory (TNF-α) responses were not modified significantly; the heterologous vaccine (G3) increased levels of CD4+ cells, a subset that sustains antiviral adaptative immunity, and avoids T-cell exhaustion.En la COVID-19, la inmunidad es fundamental. Poco se sabe de los mecanismos del factor de necrosis tumoral (TNF-α) y su capacidad de estimular la producción de anticuerpos anti-SARS-CoV-2. Asimismo, sobre la respuesta y agotamiento celular de los linfocitos T (LT). Objetivo: Evaluar el comportamiento, antes y después de la tercera dosis de vacunación, de los niveles de IgG (anti-spike), TNF-α y poblaciones linfocitarias incluyendo su agotamiento celular. Material y métodos: Se utilizó suero y células mononucleares de sangre periférica de sujetos con infección (G1, n=07) y asintomáticos (G2, n= 08 y G3, n=10) vacunados con la tercera dosis de la vacuna BNT162b2 (G1 y G2) o de ChAdOx1-S (G3). Se usó ELISA para determinar los niveles de IgG y TNF-α y citometría de flujo para determinar los niveles y el agotamiento celular de LT. Resultados: La IgG (anti-spike) antes y después de la tercera dosis no cambió. Se observó en G1 un aumento significativo de TNF-α después de recibir la tercera dosis. Los linfocitos totales (T, B y NK) mostraron una disminución significativa en G2 y, aunque los LT(CD3+) no variaron, en G3 sí hubo una disminución de LTCD4+ con aumento de PD-1+ y un aumento de LTCD8+ y PD-1+ antes y después de la tercera dosis, respectivamente. Se encontró una correlación positiva después de la tercera dosis en G3 entre IgG y CD4+PD-1+(p=0,034) y CD8+PD-1+(p=0,028), respectivamente. Conclusión: La respuesta humoral (IgG) e inflamatoria (TNF-α) no se modificó significativamente; la vacunación heteróloga (G3) incrementó los niveles de LT CD4+, una subpoblación que sostiene la inmunidad adaptativa antiviral. Adicionalmente, evito el agotamiento celular de LT.Universidad Peruana Cayetano Heredia2024-09-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed articleArtículo evaluado por paresapplication/pdfhttps://revistas.upch.edu.pe/index.php/RMH/article/view/525810.20453/rmh.v35i3.5258Revista Médica Herediana; Vol. 35 No. 3 (2024): Julio - Setiembre; 130-141Revista Médica Herediana; Vol. 35 Núm. 3 (2024): Julio - Setiembre; 130-141Revista Medica Herediana; v. 35 n. 3 (2024): Julio - Setiembre; 130-1411729-214X1018-130Xreponame:Revistas - Universidad Peruana Cayetano Herediainstname:Universidad Peruana Cayetano Herediainstacron:UPCHspahttps://revistas.upch.edu.pe/index.php/RMH/article/view/5258/5806Derechos de autor 2024 Ivan Lozada Requena, Diego Paredes Inofuentehttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:revistas.upch.edu.pe:article/52582024-09-28T01:16:40Z |
| score |
12.80667 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).